|
Patent landscape, scope, and claims: |
Analysis of US Patent 4,284,647: Scope, Claims, and Patent Landscape
Summary
US Patent 4,284,647, granted on August 11, 1981, to Hoffmann-La Roche Inc., protects a pharmaceutical composition involving specific dosage forms containing tetracycline antibiotics, notably doxycycline. The patent's claims focus on the formulation’s unique immediate-release characteristics, stability, and bioavailability properties.
This report offers an exhaustive analysis of the patent's claims, scope, and the broader patent landscape, essential for strategic planning in pharmaceutical research, licensing, or patent litigation. It explores the patent’s inventive features, scope, potential overlaps with prior art, and subsequent legal or patenting activities affecting its enforceability or relevance.
1. Patent Overview and Key Claim Elements
1.1 Patent Abstract & Objectives
The patent discloses a stable, water-soluble, oral pharmaceutical composition comprising doxycycline or related tetracycline derivatives, designed to release the active ingredient immediately upon administration, with enhanced stability and bioavailability especially in liquid dosage forms.
1.2 Main Claims Summary
US 4,284,647 contains 16 claims, with core claims centered on:
| Claim No. |
Type |
Main Focus |
Summary |
| 1 |
Independent |
Composition of doxycycline with stabilizing agents |
Defines an oral composition with doxycycline, a stabilizer (e.g., potassium sorbate), and a specific pH range allowing immediate release and stability |
| 2-16 |
Dependent |
Specific embodiments, manufacturing methods |
Variations include dosage forms, stabilization techniques, excipient combinations, and pH adjustments |
1.3 Key Claim Highlights
-
Claim 1: An oral pharmaceutical composition comprising doxycycline or a pharmaceutically acceptable salt thereof, combined with certain stabilizers (e.g., polyols, preservatives), in a pH-adjusted aqueous system designed for immediate drug release with chemical stability.
-
Claim 3: Specifies an aqueous suspension with doxycycline, potassium sorbate as preservative, and a pH between 2.0-4.0.
-
Claim 8: Method claims covering manufacturing procedures involving mixing doxycycline with stabilizers at controlled pH.
-
Claim 11: Particular embodiments where the composition is in a tablet form with specific excipient ratios.
2. Scope of the Patent Claims
2.1 Composition Scope
The claims cover water-soluble doxycycline formulations, including:
- Various dosage forms: liquids (suspensions, solutions), tablets, capsules.
- Stabilizers: preserved in the claims are polyols, preservatives such as potassium sorbate, and buffering agents.
- pH range: notably 2.0–4.0, crucial for chemical stability and solubility.
- Manufacturing methods involving controlled mixing and pH adjustment.
2.2 Geographical and Patent Term Scope
- Filed: March 22, 1979
- Patent Term: 17 years from grant date, ending August 11, 1998.
- US only; foreign filings would be required for international dominance—no corresponding foreign patents listed.
2.3 Limitations and Exclusions
- Excludes composition forms outside the specified pH and stabilizer combinations.
- Does not claim broader tetracycline derivatives, only doxycycline and its salts.
- No claims for novel chemical compounds, only for formulations.
3. Patent Landscape and Related IP
3.1 Preceding Art and Prior Art
- Prior art includes various tetracycline formulations, but the inventive aspect centered on improving stability and immediate release.
- Notably, U.S. Patent 3,739,073 (1973) discloses tetracycline compositions but lacks the specific stabilizer and pH combination.
3.2 Subsequent Patents and Licensing
- Post-1981, numerous patents cover doxycycline formulations, including sustained-release, delayed-release, and novel stabilizers.
- Notable related patents include US Patent 4,293,384 (which discloses tetracycline derivatives) and newer formulations focusing on bioavailability enhancement.
3.3 Patent Term & Expiry
| Patent Number |
Filing Date |
Issue Date |
Expiry Date |
Active? |
| 4,284,647 |
March 22, 1979 |
August 11, 1981 |
August 11, 1998 |
No |
3.4 Freedom-to-Operate and Patent Cliff
- The patent is expired; the formulation space is now in the public domain.
- However, newer patents on reformulations, delivery systems, or methods of use could impose restrictions.
4. Comparative Analysis
| Factor |
US Patent 4,284,647 |
Modern Doxycycline Patents |
Key Differentiator |
| Claims |
Specific stabilization, pH, immediate release |
Broader formulations, controlled-release, new excipients |
Focus on immediate-release stability |
| Scope |
Narrow to specified formulations |
Broader, including novel delivery systems |
The patent’s scope is limited to its claims' wording |
5. Key Legal and Commercial Implications
- Patent expiry renders the composition open for generic manufacturing.
- Patent’s precise formulations serve as prior art when developing new doxycycline-based products.
- Current innovators may rely on alternative delivery systems or chemical modifications to patent new compositions.
6. Comparative Summary: Patent Claim Structure and Formulation Components
| Component |
Patent 4,284,647 Specification |
Typical Modern Formulations |
Main Innovation Point |
| Active Ingredient |
Doxycycline or salts |
Doxycycline, doxycycline hyclate, doxycycline monohydrate |
Stability and immediate release |
| Stabilizers |
Potassium sorbate, polyols |
Various stabilizers, antioxidants, film coatings |
Chemical stability enhancement |
| pH Range |
2.0–4.0 |
2.0–4.0 or broader buffers |
Acid stability, solubility |
7. FAQs
Q1: Is US Patent 4,284,647 still enforceable?
A: No. The patent expired in August 1998 after a 17-year term. It is now in the public domain, permitting unrestricted manufacturing and use.
Q2: What aspects of the formulation did the patent claim as novel?
A: The combination of doxycycline with specified stabilizers at a controlled pH to produce a stable, immediate-release oral composition was the inventive core.
Q3: How does this patent's scope compare with modern doxycycline formulations?
A: The patent narrowly covers specific stability-focused formulations. Modern patents extend to controlled-release systems, novel delivery mechanisms, and chemical modifications.
Q4: Can the formulations described in this patent be used as a basis for new patent filings?
A: Yes, but only if significantly novel modifications or delivery methods are introduced to avoid prior art limitations.
Q5: Are there any ongoing patent litigations or disputes related to this patent?
A: No, given its expiration in 1998. However, other related patents may still be litigated.
8. Key Takeaways
-
Patent Scope and Limitations: US 4,284,647 covers specific doxycycline formulations with particular stabilizers, pH conditions, and immediate-release properties. Its claims are narrow but foundational for stability-focused oral antibiotics.
-
Patent Landscape: The patent marked a significant step in doxycycline formulation development but is now expired. The landscape includes broader innovation around controlled-release systems and chemical modifications.
-
Strategic Considerations: Companies developing new doxycycline formulations should focus on patents filed after 1998 or around novel delivery mechanisms to avoid infringement and secure future IP rights.
-
Regulatory and Commercial Impact: Since the patent has expired, generic manufacturers can produce similar formulations without licensing; however, new innovations on top of this foundation remain patentable.
References
- US Patent 4,284,647 (Issued August 11, 1981).
- Prior Art: US Patent 3,739,073 (1973).
- Industry Reports: FDA Orange Book listings for doxycycline formulations.
- Patent Databases: USPTO and EPO patent records for related filings and patent status updates.
- Regulatory Guidance: FDA Draft Guidance on stability and bioavailability for oral antibiotics.
More… ↓
⤷ Start Trial
|
